Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.419, 2003-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Imatinib mesylate promising for CML
Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. :
Access to resources
Recommend
Surpassing the success of imatinib mesylate in CML
Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. :
First-line imatinib mesylate worth it in CML
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. :
First-line imatinib mesylate worth it in CML
Inpharma, Vol. 1, Iss. 1378, 2003-01 ,pp. :
Imatinib mesylate: best first-line pharmacotherapy for CML
Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. :